A cautionary note has been sounded on off-label use of DOACs in patients with left ventricular thrombi, with researchers warning it is associated with a higher risk of stroke or systemic embolism than warfarin. A US study, published in JAMA Cardiology, suggests extrapolating from DOAC use in approved indications such as non-valvular AF is problematic. ...
Caution on off-label DOAC use in LV thrombus
By Michael Woodhead
28 Apr 2020